Power and sample size determination for noninferiority trials using an exact method.
Noninferiority studies are frequently conducted to justify the development of new drugs and vaccines that have been shown to offer better safety profiles, easier administration, or lower cost while maintaining similar efficacy as compared to the standard treatment. Recently, exact methods have been developed to address the concern that existing asymptotic methods for analyzing and planning noninferiority may fail because of small sample size or because of skewed or sparse data structure. In this paper, we explore the use of exact methods in determining sample size and power for noninferiority studies that focus on the difference of two proportions. The methodology for sample size and power calculations is developed based on an exact unconditional test of noninferiority. We illustrate this exact method using a clinical trial example in childhood nephroblastoma and briefly discuss the optimal sample-size allocation strategy. This exact unconditional method performs very well in various scenarios and compares favorably to its asymptotic counterpart in terms of sensitivity. Therefore, it is a very desirable tool for planning noninferiority trials, especially in situations where asymptotic methods are likely to fail.
Chan
Ivan S F
IS
Clinical Biostatistics, Merck Research Laboratories, UN-A102, PO Box 4, West Point, PA 19486, USA. ivan_chan@merck.com
D000465:Algorithms; D002648:Child; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D011338:Probability Theory; D012107:Research Design; D018401:Sample Size; D009396:Wilms Tumor / Q000188:drug therapy